Although the above combinatorial strategies are attractive to harness the beneficial effects of GM-CSF and concurrently suppress its pro-tumorigenic functions, additional studies are needed to determine which cancer types will benefit from these combination regimens and whether GM-CSF can be safely co-administered with other therapies or must be delivered in a staggered fashion. This evidence concerns the gene CSF2 and cancer.